---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-092216"
form_type: "8-K"
ticker: "VSTM"
cik: "0001526119"
company_name: "Verastem, Inc."
filed_at: "2026-08-06T23:33:15+00:00"
generated_at: "2026-08-07T10:05:43.321915+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Verastem adds up to $75M Revenue Notes; $50M tranche set for Aug 28, 2026

## Summary
- Amendment No. 3 creates new Revenue Notes series (up to $75M) replacing conditional $25M and $50M Initial Note tranches.
- $50M tranche issues Aug 28, 2026; optional $25M tranche open until May 15, 2027 if quarterly avutometinib/defactinib net sales hit $40M.
- Revenue Payment Percentage is 4.50%, falling to 1.75% after Dec 31, 2031 if cumulative payments reach 100% of Funded Amount; maturity June 30, 2033.
- Repayment amounts range from 135% to 185% of Funded Amount depending on timing; up to 25% can be paid in VSTM common stock on US IP sale.
- Initial Notes' $75M principal, 9.75% interest cap, and no financial covenants remain; obligations secured by substantially all assets.

## SEC filing metadata
- accession: 0001104659-26-092216
- form_type: 8-K
- ticker: VSTM
- cik: 0001526119
- company_name: Verastem, Inc.
- filed_at: 2026-08-06T23:33:15+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1526119/000110465926092216/0001104659-26-092216-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1526119/000110465926092216/tm2622452d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-092216
- JSON: https://secwatch.observer/filing/0001104659-26-092216.json
- Plain text: https://secwatch.observer/filing/0001104659-26-092216.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.